hesperidin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
hesperidin — increases flow-mediated dilation
Evidence strength: very limited.Finding“In the clinical study, when compared with placebo, hesperidin treatment increased flow-mediated dilation (10.26 ± 1.19 vs. 7.78 ± 0.76%; P = 0.02) and reduced concentrations of circulating inflammatory biomarkers (high-sensitivity C-reactive protein, serum amyloid A protein, soluble E-selectin).”
Quoted verbatim from Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome.. - Study
- crossover
- Duration
- 3 weeks
- Dose
- 500 mg once daily for 3 weeks
- Population
- Adults with metabolic syndrome (n = 24); randomized placebo-controlled double-blind crossover trial of oral hesperidin
Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome.2011PMID:2134606510.1210/jc.2010-2879Permalink
To cite this finding: https://catalystproject.ai/e/01M5MET7HV7GWTDE6CH1NWK7NF